Methods of treating skin cancers
AssigneeMediWound Ltd.
InventorsLior ROSENBERG, Dafna GEBLINGER, Eilon ASCULAI
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating skin cancers utilizing pharmaceutical formulations in the form of a hydrogel that includes a proteolytic enzyme mixture obtained from bromelain and a water-soluble gelling agent. In particular, the method is useful for treating non-melanoma skin cancers, pre-cancerous skin lesions, and benign skin lesions.
Claims21
-35. (canceled)
A method of treating a skin lesion and delaying or preventing recurrence thereof comprising topically applying to a skin lesion of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical formulation comprising:
- (a) a composition in a dry or powdered form comprising:
- (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32);
- (ii) a water-soluble gelling agent;
- (iii) optionally, an anti-aggregation agent;
- (iv) a pH adjusting agent;
- and
- (b) water,
- wherein, prior to use, the composition (a) is admixed with the water (b) to form the pharmaceutical formulation characterized by being a hydrogel having a pH ranging from about 6.0 to about 8.0,
- wherein the amount of the proteolytic enzyme mixture obtained from bromelain ranges from about 0.5% (w/w) to about 10% (w/w) of the total weight of said pharmaceutical formulation, and
- wherein the skin lesion is selected from the group consisting of a non-melanoma skin cancer, pre-cancerous skin lesions, and benign skin lesions, thereby treating said skin lesion and delaying or preventing recurrence thereof.
A method of treating a skin lesion and delaying or preventing recurrence thereof comprising topically applying to a skin lesion of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical formulation comprising:
- (a) a composition in a dry or powdered form comprising:
- (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32);
- (ii) a water-soluble gelling agent of guar gum in an amount ranging from about 0.25% (w/w) to about 5% (w/w) of the total weight of the pharmaceutical formulation;
- (iii) an anti-aggregation agent of lactose in an amount ranging from about 10% (w/w) to about 25% (w/w) of the total weight of the pharmaceutical formulation;
- (iv) a pH adjusting agent;
- and
- (b) water in an amount to complete to 100% (w/w) of the total weight of the pharmaceutical formulation,
- wherein, prior to use, the composition (a) is admixed with the water (b) to form the pharmaceutical formulation characterized by being a hydrogel having a pH ranging from about 6.0 to about 8.0,
- wherein the amount of the proteolytic enzyme mixture obtained from bromelain ranges from about 0.5% (w/w) to about 10% (w/w) of the total weight of said pharmaceutical formulation, and
- wherein the skin lesion is selected from the group consisting of a non-melanoma skin cancer, pre-cancerous skin lesions, and benign skin lesions, thereby treating said skin lesion and delaying or preventing recurrence thereof.
A method of treating a skin lesion and delaying or preventing recurrence thereof comprising topically applying to a skin lesion of a subject in need of such treatment a therapeutically effective amount of a pharmaceutical formulation in the form of a hydrogel having a pH ranging from about 6.0 to about 8.0, the hydrogel formed from:
- (c) a composition comprising:
- (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32);
- (ii) a water-soluble gelling agent;
- (iii) optionally, an anti-aggregation agent;
- (iv) a pH adjusting agent;
- and
- (d) water,
- wherein the amount of the proteolytic enzyme mixture obtained from bromelain ranges from about 0.5% (w/w) to about 10% (w/w) of the total weight of said pharmaceutical formulation, and
- wherein the skin lesion is selected from the group consisting of a non-melanoma skin cancer, pre-cancerous skin lesions, and benign skin lesions, thereby treating said skin lesion and delaying or preventing recurrence thereof.
Dependencies are inferred from the claim text.